The Third National Hepatitis C Strategy 2010 - 2013

References

Page last updated: July 2010

(Endnotes)

  1. National Centre in HIV Epidemiology and Clinical Research (NCHECR), 2009, National Surveillance Report.
  2. Razali K, Amin J, Dore GJ & Law MG 2009, HCV Projections Working Group, ‘Modelling and calibration of the hepatitis C epidemic in Australia’, Statistical Methods in Medical Research, 18(3), pp. 253–270.
  3. Razali K, et al. 2007, Modelling the hepatitis C virus epidemic in Australia, Drug and Alcohol Dependence, vol. 91, no. 2–3, pp. 228–35.
  4. Ministerial Advisory Committee on AID, Sexual Health and Hepatitis C Subcommittee 2008, ‘Hepatitis C prevention, treatment and care: Guidelines for Australia Custodial Settings’.
  5. Butler T & Papanastasiou C 2008, National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004 and 2007. National Drug Research Institute (Curtin University) and the National Centre in HIV Epidemiology and Clinical Research (University of New South Wales).
  6. Hepatitis C Virus Projections Working Group 2006, Estimates and Projections of the Hepatitis C Virus Epidemic in Australia 2006. Canberra: Hepatitis C Sub-Committee, Ministerial Advisory Committee on AIDS Sexual Health and Hepatitis.
  7. Maher L, Jalaludin B, Chant K, Jayasuriya R, Sladden T, Kaldor JM & Sargent PL 2006, ‘Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia’, Addiction, vol. 101, pp. 1499–1508.
  8. Thein HH & Dore G 2009, ‘Natural history of hepatitis C virus infection’, In Dore G, Temple-Smith, M & Lloyd A Hepatitis C: An expanding perspective. IP Communications, Sydney.
  9. Manns MP, McHutchison JG, Gordon SC, et al. ‘Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial’, Lancet 2001;358: pp. 958–965.
  10. Fried MW, Shiffman M, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 2002, vol. 347: pp. 975–982.
  11. Thein HH & Dore G 2009, Cancer Forum.
  12. The Ottawa Charter for Health Promotion is a 1986 document produced by the World Health Organization. It was launched at the first international conference for health promotion that was held in Ottawa, Canada.
  13. Bryant J, Topp L, Hopwood M, Iversen J, Treloar C & Maher L, ‘Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south east Sydney’, Drug and Alcohol Review. In press. Accepted September 2009.
  14. Maher L, Jalaludin B, Chant K, Jayasuriya R, Sladden T, Kaldor JM & Sargent PL 2006, ‘Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia’, Addiction, vol. 101, pp. 1499–1508.
  15. Crockett B & Gifford S 2004, ‘Eyes wide shut’: narratives of women living with hepatitis C in Australia. Women and Health, 39(4): pp. 117–137.
  16. Bryant J, Brener L, Hull P & Treloar C ‘Needle sharing in sexual relationships: Serodiscordance and the gendered character of injecting’, Drug and alcohol dependence. In press. Accepted October 2009.
  17. Maher L, Jalaludin B, Chant K, Jayasuriya R, Sladden T, Kaldor JM & Sargent PL 2006, ‘Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia’, Addiction, 101, pp. 1499–1508.
  18. Thein HH & Dore G 2009, ‘Natural history of hepatitis C virus infection’, In Dore G., Temple-Smith, M. & Lloyd A. Hepatitis C: An expanding perspective. IP Communications, Sydney.
  19. NCHECR, 2009, National Surveillance Report.
  20. Ibid.
  21. O’Brien S, Day C, Black E, Thetford C & Dolan K 2006, Injecting Drug Users’ Understanding of Hepatitis C, National Drug and Alcohol Research Centre, technical report no. 262, New South Wales, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
  22. Treloar C, Abelson J, Cao W, Brener L, Kippax S, Schultz M & Bath N, Barriers and incentives to treatment for illicit drug users. Canberra: Commonwealth of Australia, 2004, National Drug Strategy Monograph Series no. 5.
  23. Ross J, Cohen J, Darke S, Hando J & Hall , 1994, ‘Transition between routes of administration and correlates of injecting amongst regular amphetamine users’, NDARC Monograph.
  24. Queensland Alcohol & Drug Research and Education Centre, 2005, Beyond Transmission: Guidelines for hepatitis C education targetting young people who inject drugs.
  25. Abelson A, Treloar C, Crawford J, Kippax S, van Beek I & Howard J, ‘Some characteristics of early onset injecting drug users prior to and at the time of their first injection’, Addiction. 2006; 101: pp. 548–55.
    Top of Page
  26. Van Beek I, Dwyer R, Dore G, Luo K & Kaldor J, 1998, ‘Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study’, British Medical Journal 1998; 317: pp. 433–437.
  27. Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis, Hepatitis C Subcommittee, 2008, Hepatitis C Prevention, Treatment and Care: Guidelines for Australian Custodial Settings. July.
  28. Butler T & Papanastasiou C 2008, National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004 and 2007. National Drug Research Institute (Curtin University) & National Centre in HIV Epidemiology and Clinical Research (University of New South Wales).
  29. van der Pooten D, Kenny DT & George J ‘Prevalence and Risk Factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders’, Medical Journal of Australia 2008; 188 (10): pp. 610–614 <http://www.mja.com.au/public/issues/188_10_190508/van10170_fm.html#0_pgfId-1092050>
  30. Dolan K, Rutter S & Wodak AD 2002, ‘Prison-based syringe exchange programmes: a review of international research and development’ Addiction, vol. 98, pp. 153–158.
  31. Dolan K, Shearer J, White B, Zhou J, Kaldor J & Wodak AD 2005, ‘Four-year Follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection’, Addiction, 100, pp. 820–828.
  32. Dolan K, Shearer J, White B, Zhou J, Kaldor J & Wodak AD 2005, ‘Four-year Follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection’, Addiction, 100, pp. 820–828.
  33. Caruana SR, Kelly HA, De Silva SL, Chea L, Nuon S, Saykao P, Bak N & Biggs BA et al. 2005, ‘Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the Mekong region’, Australian and New Zealand Journal of Public Health, 29(1).
  34. Razali K, Thein HH, Bell JU, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O & Law M, 2007, ‘Modelling the hepatitis C virus epidemic in Australia’, Drug and Alcohol Dependence. 1;91 (2–3): pp. 228–35.
  35. Mikhailovich K & Arabena K 2005, ‘Evaluating an indigenous sexual health peer education project’, Health Promotion Journal of Australia 16(3): pp. 189–193.
  36. Treloar C & Abelson J, 2005, ‘Information exchange among injecting drug users: a role for an expanded peer education workforce’, International Journal of Drug Policy 16: 46–63.
  37. Treloar C, Laybutt B, Jauncey M, van Beek I, Lodge M, Malpas G & Carruthers S 2008, ‘Broadening discussions of ‘safe’ in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice’, International Journal of Drug Policy 19: pp. 59–65.
  38. Bryant J, Wilson H, Hull P & Treloar C 2009, Drug use, hepatitis C and exposure to injecting among young people in Queensland: The Big Day Out survey 2009. Sydney: National Centre in HIV Social Research.
  39. Bryant J & Hopwood M 2009, ‘Secondary exchange of sterile injecting equipment in a high distribution environment: A mixed method analysis in south east Sydney, Australia’, International Journal of Drug Policy 20: 324:328.
  40. Barrett D & Lines R et al. 2008, Recalibrating the regime: The need for a human rights-based approach to international drug policy. London: Beckley Foundation Drug Policy Programme.
  41. National Centre for HIV Epidemiology and Clinical Research, 2009, Return on Investment 2: Evaluating the cost-effectiveness of Needle and syringe programs in Australia. University of New South Wales.
  42. Ibid., p. 32.
  43. Intergovernmental Agreement (IGA) on Federal Financial Relations <http:// www.coag.gov.au/intergov_agreements/federal_financial_relations/index.cfm>
  44. Anti-Discrimination Board of New South Wales (ADBNSW), 2001, C-Change—Report of the enquiry into hepatitis C related discrimination. Sydney: Anti-Discrimination Board of New South Wales.
  45. Treloar C & Cao W 2005, ‘Access to harm reduction services and "hidde" injectors: Barriers to NSP use in a high drug use area of Sydney, New South Wales’, International Journal of Drug Policy 16: pp. 308–15.
  46. Hopwood M, Treloar C & Bryant J, 2006, ‘Hepatitis C and injecting-related discrimination within healthcare in New South Wales, Australia’, Drugs: Education, Prevention and Policy 13: pp. 61–75.
  47. Treloar CJ & Hopwood MN 2004, ‘Infection control in the context of hepatitis C disclosure: Implications for education of healthcare professionals’, Education for Health, 17(2), pp. 183–191.
  48. Hepatitis Australia 2009, Do you C what I C?, report on the information and support needs of people living with hepatitis C in Australia. Canberra: Hepatitis Australia.
  49. Ahern J & Stuber J et al. 2007, ‘Stigma, discrimination and the health of illicit drug users’, Drug and Alcohol Dependence, vol. 88: pp. 188–196.
  50. Department of Health & Ageing 2005, National Hepatitis C Strategy, 2005–2008, Canberra, Commonwealth of Australia.
    Top of Page
  51. Deacon R, Newland J, Harris C, Treloar C & Maher L 2002, Hepatitis C seroconversion: Using qualitative research to enhance surveillance, National Centre for HIV Epidemiology and Clinical Research and National Centre in HIV Social Research, Sydney.
  52. National Centre for HIV Epidemiology and Clinical Research 2009, HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney.
  53. Aitken C & Kerger M et al. 2002, ‘Peer-delivered hepatitis C testing and counselling: A Means of improving the health of injecting drug users’, Drug and Alcohol Review, vol. 21: pp. 33–37.
  54. National Centre for HIV Epidemiology and Clinical Research 2009, Return on Investment 2: Evaluating the cost-effectiveness of Needle and syringe programs in Australia. University of New South Wales.
  55. National Centre for HIV Epidemiology and Clinical Research 2009, Return on Investment 2: Evaluating the cost-effectiveness of Needle and syringe programs in Australia. University of New South Wales.
  56. McNally S & Latham S 2009, Recognising and responding to hepatitis C in indigenous communities in Victoria, Australian Research Centre in Sex, Health and Society, Melbourne.
  57. Norman J, Walsh NM, Mugavin J, Stoové MA, Kelsall J, Austin K & Lintzeris N 2008, ‘The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users’, Harm Reduction Journal, 5(8).
  58. Treloar C & Fraser S 2009, Hepatitis C treatment: Increasing treatment uptake needs a critical view [Commentary]. Drug and Alcohol Review, vol. 28: pp. 436–40.
  59. Treloar C, Newland J, Rance J & Hopwood M ‘Uptake and delivery of hepatitis C treatment in opiate substitution treatment: Perceptions of clients and health professionals’, Journal of Viral Hepatitis. In press. Accepted November 2009.
  60. Australian National Committee for HIV, Hepatitis C and Related Diseases, Model of Care for People with Hepatitis C. 2003.
  61. Bradford D, Hoy J & Matthews G (eds), HIV, viral hepatitis and STIs: a guide for primary care, Australian Society for HIV Medicine, Sydney.
  62. MacDonald et al. 1997 and 2000, Australian Needle and Syringe Program (NSP) Survey, University of New South Wales, Sydney.
  63. National Centre in HIV Epidemiology and Clinical Research 2008, ‘Australian NSP Survey National Data Report 2003–2007’, National Centre in HIV Epidemiology and Clinical Research, University of NSW.
  64. Topp, L et.al. ‘Representativeness of Injecting Drug Users Who Participate in HIV Surveillance: Results From Australia’s Needle and Syringe Program Survey’, Journal of Acquired Immune Deficiency Syndromes 2008, 47, 5, pp. 632–638 <http://journals.lww.com/jaids/Fulltext/2008/04150/Representativeness_of_Injecting_Drug_Users_Who.15.aspx>.
  65. Kwon JA, Iversen, J, Maher L, Law MG & Wilson DP 2009, ‘The Impact of Needle and Syringe Programs on HIV and HCV Transmissions in Injecting Drug Users in Australia: A Model-Based Analysis’, Journal of Acquired Immune Deficiency Syndrome, August 1; 51(4).
  66. Bryant J & Treloar C 2006, Risk practices and other characteristics of injecting drug users who obtain injecting equipment from pharmacies and personal networks. International Journal of Drug Policy 17: pp. 418–24.
  67. Bryant J, Topp L, Hopwood M, Iversen J, Treloar C & Maher L, ‘Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south east Sydney’, Drug and Alcohol Review. In press. Accepted September 2009.
  68. New South Wales Health and Hardwick Consulting, 2008, Review of Hepatitis C Treatment and Care Services. Sydney.
Top of Page